@article{cb39b75ae97d40be930d40ae2c34cb7d,
title = "Bipolar androgen therapy in the treatment of prostate cancer",
author = "Denmeade, {Samuel Ray}",
note = "Funding Information: SD Our group has conducted 3 studies in this area. Our pilot study was sponsored by the One-in-Six Fund, which was started by a patient of mine to support prostate cancer research. The study, whose results appeared in Science Translational Medicine in 2015, was conducted in 14 men with castration-resistant prostate cancer (CRPC), who received a monthly testosterone injection (400 mg) and 2 weeks of daily etoposide (100 mg) while continuing to undergo ADT. After 3 cycles, the men whose prostate-",
year = "2018",
month = jun,
language = "English (US)",
volume = "16",
pages = "408--411",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "6",
}